The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Ovarian Cancer National Alliance and Ovarian Cancer Research Fund merge

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

THE OVARIAN CANCER NATIONAL ALLIANCE and the OVARIAN CANCER RESEARCH FUND announced a merger, forming the Ovarian Cancer Research Fund Alliance. The new body will be the largest global organization dedicated to advancing ovarian cancer research.

“The Ovarian Cancer Research Fund Alliance believes we can gain more ground together, fighting disease through a ‘one-stop shop’ approach to research, advocacy, education and awareness,” said OCRFA President and CEO Audra Moran. “The formation of OCRFA will propel ovarian cancer prevention and treatment forward at an accelerated pace.”

Between the two organizations, nearly $70 million has been invested over the past 22 years in research grants to diagnose, treat and cure ovarian cancer.

“This merger will unite the ovarian cancer community under one strong voice. OCRFA is committed to continuing and expanding the many patient-centered programs begun by both the Ovarian Cancer National Alliance and Ovarian Cancer Research Fund in the past, including, the Ovarian Cancer National Conference, Survivors Teaching Students and Woman to Woman,” said OCRFA Executive Vice President Calaneet Balas.

Table of Contents

YOU MAY BE INTERESTED IN

News Analysis

HHS presents new protein-forward dietary guidelines, turning the food pyramid upside down
The Kennedy guidelines are mum on cancer risks associated with red meat and alcohol

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
By Claire Marie Porter
Guest Editorial

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
Draft guidance consolidates trial design updates for developers

In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 
By Nicholas Richardson
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account